All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth

van Saene, Hendrick K. F.; Petros, Andy J.; Ramsay, Graham; Baxby, Derrick
May 2003
Intensive Care Medicine;May2003, Vol. 29 Issue 5, p677
Academic Journal
journal article
Objective: The objective was to compare evidence of the effectiveness, costs and safety of the traditional parenteral antibiotic-only approach against that gathered from 53 randomised trials involving more than 8,500 patients and six meta-analyses on selective decontamination of the digestive tract (SDD) to control infection on the intensive care unit (ICU). PHILOSOPHY: Traditionalists believe that all infections are due to breaches of hygiene except those established in the first 2 days, and that all micro-organisms can cause death. In contrast, newer insights show that transmission via the hands of carers are responsible only for infections occurring after one week, and that only a limited range of 15 potential pathogens contribute to mortality. INTERVENTIONS TO PREVENT ICU INFECTION: The traditional approach is based on hand disinfection aiming at the prevention of transmission of all micro-organisms, to control all infections that occur after 2 days on the ICU. The second feature is the restrictive use of systemic antibiotics, only in cases of microbiologically proven infection. In contrast, SDD aims to control the three types of infection: primary, secondary endogenous and exogenous due to 15 potential pathogens. The classical SDD tetralogy comprises four components: (i) a parenteral antibiotic, cefotaxime, administered for three days to prevent primary endogenous infections typically occurring "early"; (ii) the oropharyngeal and enteral antimicrobials, polymyxin E, tobramycin and amphotericin B administered in throat and gut throughout the treatment on the ICU to prevent secondary endogenous infections tending to develop "late"; (iii) a high standard of hygiene to control transmission of potential pathogens; and (iv) surveillance samples of throat and rectum to monitor the efficacy of the treatment.Endpoints: (i) Infectious morbidity; (ii) mortality; (iii) antimicrobial resistance; and (iv) costs.Results: Properly designed trials on hand disinfection have never demonstrated a reduction in either pneumonia and septicaemia, or mortality. Two randomised trials using restrictive antibiotic policies failed to show a survival benefit at 28 days. In both trials the proportion of resistant isolates obtained from the lower ways was >60% despite significantly less use of antibiotics in the test group. A formal cost effectiveness analysis of the traditional antibiotic policies has not been performed. On the other hand, two meta-analyses have shown that SDD reduces the odds ratio for lower airway infections to 0.35 (0.29-0.41) and mortality to 0.80 (0.69-0.93), with a 6% overall mortality reduction from 30% to 24%. No increase in the rate of super infections due to resistant bacteria could be demonstrated over a period of 20 years of clinical research. Four randomised trials found the cost per survivor to be substantially lower in patients receiving SDD than for those traditionally managed.Conclusions: The traditionalists still rely on level 5 evidence, i.e. expert opinion, with a grade E recommendation, whilst the proponents of SDD are able to cite level 1 evidence allowing a grade A recommendation in their attempts to control infection on the ICU. The main reason for SDD not being widely used is the primacy of opinion over evidence.


Related Articles

  • Systematic surveillance cultures as a toolto predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. Depuydt, P.; Benoit, D.; Vogelaers, D.; Decruyenaere, J.; Vandijck, D.; Claeys, G.; Verschraegen, G.; Blot, S. // Intensive Care Medicine;Apr2008, Vol. 34 Issue 4, p675 

    To assess prediction of multidrug resistant (MDR) pathogens in ventilator-associated pneumonia (VAP) by systematic surveillance cultures (SC) and to assess the contribution of SC to initial antibiotic therapy. Prospective cohort study of patients with microbiologically confirmed VAP. Comparison...

  • Healthcare-Associated Pneumonia in the Intensive Care unit. Kollef, Marin H. // Current Medical Literature: Respiratory Medicine;2009, Vol. 23 Issue 4, p81 

    The article focuses on healthcare-associated pneumonia (HCAP) as distinct type of pneumonia. In contrast to community acquired pneumonia (CAP), the pathogens in HCAP are often multiple drug resistant (MDR) bacteria and when risk factors for HCAP is present, the initial use of broad spectrum...

  • Towards Gene Therapy for Inflammatory and Infective Pulmonary Diseases. Simpson, A J; King, J A; Thorpe, P H; Mclachlana, G; Sallenave, J-M // Current Genomics;May2004, Vol. 5 Issue 4, p365 

    Pneumonia is responsible for unacceptably high mortality rates among specific populations of patients, despite the use of conventional antibiotics and improvements in critical care. New treatments for severe pulmonary infection are therefore required. Manipulation of host defence genes using...

  • Bactericidal Activity of Grepafloxacin Against Respiratory Pathogens. Daschner, F.; Frank, U.; Huber, K. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p376 

    Compares the in vitro activity of grepafloxacin with that of other oral antibiotics against clinical isolates of pathogens causing community-acquired respiratory tract infections. Materials and methods; Results.

  • Antimicrobial Susceptibility Among Nosocomial Pathogens Isolated in Intensive Care Units in Germany. Frank, U.; Jonas, D.; Lüpke, T.; Ribeiro-Ayeh, B.; Schmidt-Eisenlohr, E.; Rüden, H.; Daschner, F. D. // European Journal of Clinical Microbiology & Infectious Diseases;Nov2000, Vol. 19 Issue 11, p888 

    This article presents information on antimicrobial susceptibility among nosocomial pathogens isolated in intensive care units in Germany. Knowledge of current trends in the development of resistance against available and new antimicrobial agents is an important prerequisite for the effective...

  • Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen. Georges, B.; Conil, J.-M.; Cougot, P.; Decun, J.-F.; Archambaud, M.; Seguin, T.; Chabanon, G.; Virenque, C.; Houin, G.; Saivin, S. // International Journal of Clinical Pharmacology & Therapeutics;2005, Vol. 43 Issue 8, p360 

    The aim of this study was to compare the pharmacokinetic and pharmacodynamic parameters of a continuous in- fusion of cefepime vs. an intermittent regimen in critically ill adult patients with Gram-negative bacilli infection. The prospective randomized parallel study was carried out in 50...

  • Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant Organisms. Niederman, Michael S. // Clinical Infectious Diseases;1/2/2006, Vol. 42, pS72 

    Among various risk factors for death among critically ill patients with serious infection, inappropriate anti-microbial therapy is an important factor that clinicians can modify directly. The presence of multidrug-resistant bacteria is the primary reason that patients with ventilator-associated...

  • Caracterización fenotípica de cepas de Staphylococcus coagulasa negativa aisladas de una unidad de alto riesgo neonatal. Álvarez, Maleygua; Velazco, Elsa; Nieves, Beatriz; Alviarez, Evelyn; Araque, Maria; Salazar, Elsa; Gutierrez, Betty // Revista Kasmera;ene-jun2008, Vol. 36 Issue 1, p7 

    Nosocomial infections constitute a public health problem due to a high level of morbidity and mortality, generating high health-care costs in hospitals. Intensive care units are the principal areas where a high incidence of nosocomial infections is reported. Bacterimia is the principal infection...

  • Virulence. Riedmann, Eva M.; Sharpe, Sara; Mylonakis, Eleftherios // Virulence;Nov2011, Vol. 2 Issue 6, Special section p1 

    An introduction is presented in which the editors discuss various reports within the issue on topics including the role of antimicrobial peptides in human immunity, antibiotic therapy for lower respiratory tract infections, and pathogenic microorganisms.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics